MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

TransMedics Group Inc

Closed

SectorHealthcare

94.03 1.91

Overview

Share price change

24h

Current

Min

91.15

Max

95.02

Key metrics

By Trading Economics

Income

2.6M

6.9M

Sales

13M

122M

P/E

Sector Avg

81.981

57.333

EPS

0.19

Profit margin

5.638

Employees

728

EBITDA

3.2M

16M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+8.4% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

397M

3B

Previous open

92.12

Previous close

94.03

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

TransMedics Group Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 wrz 2024, 03:29 UTC

Top News

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

8.4% upside

12 Months Forecast

Average 100 USD  8.4%

High 125 USD

Low 80 USD

Based on 8 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

88.48 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.